Notably, a variety of FDA-approved and clinical phase trial HDACIs, at therapeutically and clinically relevant doses, have been shown to alter StAR acetylation patterns and subsequently suppress E2 accumulation in human and mouse ER+ BC cells/tissues [11,20]. Here, STAR is linked to breast cancer.